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CARDIOTHORACIC TRANSPLANTATIONCombined heart-kidney transplant improves post-transplant survival
compared with isolated heart transplant in recipients with reduced
glomerular filtration rate: Analysis of 593 combined heart-kidney
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456Objective: Criteria for simultaneous heart-kidney transplant (HKTx) recipients are unclear. We characterized
the evolution of combined HKTx in the United States over time compared with isolated heart transplantation
(HTx) and determined factors maximizing post-transplant survival. We focused on whether a threshold
estimated glomerular filtration rate (eGFR) could be identified that justified combined transplantation.
Methods: A supplemented United Network Organ Sharing Dataset identified HTx and HKTx recipients from
2000 to 2010. eGFR was calculated for HTx and recipients were grouped into eGFR quintiles. Time-related
mortality was compared among recipients, with multivariable factors sought using Cox proportional hazard
regression models.
Results: We identified 26,183 HTx recipients, of whom 593 were HKTx recipients. HTx increased modestly
over time (3.6%), whereas prevalence of HKTx increased dramatically (147%). Risk-unadjusted survival
was similar among HTx recipients (8.4  0.04 years) and HKTx recipients (7.7  0.2 years) (P ¼ .76).
Isolated HTx recipients in the lowest eGFR quintile had decreased survival (P<.001), but those in the third
eGFR quintile had superior survival, suggesting a benefit in this subgroup. HTx recipients in the lowest
eGFR quintile (eGFR less than mean 37 mL/minute) had worse survival than combined HKTx recipients
(7.1 0.07 vs 7.7 0.2; P<.001). Multivariable factors for increased mortality among HTx recipients included
lower eGFR, higher recent panel reactive antibody score, older age, African American race, diabetes, longer
ischemic time, and certain diagnoses.
Conclusions: Performance of combinedHKTx is increasing out of proportion to isolatedHTx. eGFR is an impor-
tant determinant of improved HTx survival. Combined HKTx recovers post-transplant survival in patients with
eGFR<37 mL/minute and can be recommended in this subgroup. (J Thorac Cardiovasc Surg 2014;147:456-61)Supplemental material is available online.e Division of Pediatric Cardiothoracic Surgery,a Benioff Children’s Hospital,
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The Journal of Thoracic and Cardiovascular SurgThe first report of simultaneous combined heart and kidney
transplantation (HKTx) using the same donor was by
Norman and colleagues in 1978.1 Combined organ
transplantation has since become an accepted therapy for
combined kidney and cardiac failure, which frequently exist
together. Although several single-institution studies have
been published,2-4 contemporary national outcomes for
HKTx recipients are not known. Additionally, there are no
uniformly agreed upon criteria for selecting a combined
organ transplant strategy over sequential or isolated organ
transplant. We sought to characterize the evolution of HKTx
relative to isolated heart transplantation (HTx) in the United
States and determine those factors that maximize post-
transplant survival.Wewere particularly interested inwhether
a threshold estimated glomerular filtration rate (eGFR) could
be identified that justified combined transplantation.METHODS
All HTx and HKTx recipients from 2000 to 2010 were identified using a
supplemented United Network for Organ Sharing (UNOS) dataset, termedery c January 2014
Abbreviations and Acronyms
eGFR ¼ estimated glomerular filtration rate
HKTx ¼ combined heart-kidney transplant
HTx ¼ heart transplant
LVAD ¼ left ventricular assist device
UNOS ¼ United Network for Organ Sharing
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XUNOS–Standard Transplant Analysis and Research. All HKTx procedures
were performed either as simultaneous procedures, or performed
sequentially within 24 hours of 1 another. The eGFR among HTx recipients
was estimated using the widely accepted 4-variable Modification of Diet in
Renal Disease formula for adults5-7 and the Schwartz formula for recipients
younger than age 13 years.8,9 The 4-Modification of Diet in Renal Disease
formula incorporates serum creatinine, age, race, and sex, and has been
validated for patients with chronic renal disease. The Schwartz formula
(eGFR ¼ [k $ height/serum creatinine]), includes a constant, k, that varies
with age to account for variable muscle mass. The serum creatinine used in
all calculations was obtained at the most proximate measurement before
transplantation. The eGFR was then log-transformed and recipients were
grouped into eGFR quintiles. Continuous variables are reported as mean
 standard deviation, or as medians with range, and are compared across
groups using the Student t test (for normal distribution) or the Wilcoxon
rank sum test (for non-normal distribution). Comparisons among
categorical variables are presented as percentages and frequencies and
were compared across groups using the c2 test or Fisher exact test as
appropriate. The prevalence of HKTx compared with isolated HTx over
timewas calculated for each year of the study period. Time-related survival
from HTx or HKTx were described using the Kaplan-Meier method, and
risk-unadjusted differences among groups were determined using the
log-rank test. Particular attention was directed at investigating an eGFR
threshold at which combined HKTx survival provided a benefit over
isolated HTx. Multivariable factors for time-related death were sought
using Cox proportional hazard regression models. Variables considered
in multivariable models are reported in Table E1. In all cases, variable
transformations were explored and optimized to provide optimum
calibration, and year was included in all models to account for a possible
era effect. SAS software, version 9.2 (SAS Institute Inc, Cary, NC) was
used for all analyses. Institutional review board approval was obtained
under an expedited review for de-identified existing data.TRESULTS
Patient Characteristics
We identified 26,183 HTx recipients, of whom 593 were
HKTx recipients. Although the frequency of isolated
HTx increased modestly over time (3.6%), the prevalence
of HKTx increased dramatically (147%) over time
(Figure 1, A and B). Demographics and clinical characteris-
tics of the study patients segregated by recipient type are
shown in Table 1. The median patient age was 52 years
(range 0-77 years). HKTx recipients had higher serum
creatinine at the time of transplant (3.4  2.8 mg/dL vs
1.2  0.7 mg/dL), were older (51  13 years vs 45  20
years), and had a higher prevalence of diabetes (40% vs
36%), compared with HTx recipients (P< .001 for all).
A lower proportion of HKTx recipients were on left
ventricular assist device (LVAD) support compared with
HTx recipients (15.2% vs 20.4%;P¼ .003), although otherThe Journal of Thoracic and Catypes of inotropic or mechanical circulatory support were
similar among both groups. Wait-list times were not
significantly different among recipient groups (HTx:
193  351 days vs HKTx: 212  322 days; P ¼ .14).
Among isolated HTx recipients, the mean eGFR for
grouped quintiles in ascending order was: 36.6  8.9 mL/
minute, 54.8  4.1 mL/minute, 68.9  4.2 mL/minute,
87.1  6.6 mL/minute, and 140.3  56.4 mL/minute,
respectively. eGFR was negatively correlated with diabetes,
white ethnicity, being a man, and age. The most prevalent
diagnoses overall included dilated cardiomyopathy
(72%), ischemic cardiomyopathy (5%), and congenital
heart disease (7%). The majority of patients were white
(70%) and men (73%).
Renal Failure Requiring Dialysis Among Recipients
Following transplant, 155 (26%) of the combined HKTx
recipients required dialysis within 30 days, compared with
2181 (9%) of the isolated HTx recipients. Among isolated
HTx recipients, 609 (22%) of 2758 patients in the lowest
GFR quintile required early dialysis, compared with 16%
(1115 out of 6962) and 11% (1836 out of 15781) of patients
in the next 2 quintiles. Logistic regression analysis of
patients receiving isolated heart transplant, including renal
function indices (c statistic, 0.67) revealed that a higher
eGFR reduced the risk of post-transplant early dialysis
(odds ratio, 0.647; 95% confidence interval, 0.574-0.72;
P < .001) Patients in the lowest eGFR quintile had a
significantly increased risk of needing dialysis (odds ratio,
2.093; 95% confidence interval, 1.835-2.386; P<.001).
Influence of eGFR on Post-Transplant Survival
Overall survival at 1 and 5 years for the entire cohort was
88% and 73%, respectively. Risk-unadjusted survival was
similar among HTx (8.4 0.04 years) and HKTx recipients
(7.7  0.2 years; P ¼ .76) (Figure 2). Isolated HTx
recipients in the lowest eGFR quintile had significantly
decreased survival compared with the other HTx groups
(P< .001), whereas those in the third eGFR quintile had
superior survival, suggesting a benefit in this subgroup
(Figure 3).
Compared with patients receiving combined HKTx,
isolated HTx recipients in the lowest eGFR quintile
(mean eGFR <37 mL/minute) had significantly worse
median survival (7.1  0.07 years vs 7.7  0.2 years;
P<.001) (Figure 4). Multivariable analysis demonstrated
that lower eGFR (log-transformed; hazard ratio, 0.83;
P< .001), higher recent panel reactive antibody (hazard
ratio, 1.001; P < .001), older age (hazard ratio, 1.002;
P ¼ .03), African American race (hazard ratio, 1.55;
P< .001), diabetes (hazard ratio, 1.17; P< .001), longer
ischemic time (hazard ratio, 1.08; P< .001), and certain
diagnoses were risk factors for increased mortality among
HTx recipients (Table E2).rdiovascular Surgery c Volume 147, Number 1 457
FIGURE 1. A, Horizontal bar graph depicting the number of isolated heart transplants performed in each year of the study period. Actual numerical value
depicted on the right side, with calendar year on the left side. B, Horizontal bar graph depicting the number of combined heart-kidney transplants performed
in each year of the study period. Actual numerical value depicted on the right side, with calendar year on the left side.
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XDISCUSSION
Our study is the first to report contemporary national
outcomes for combined HKTx in relation to isolated HTx.
In addition, our study provides useful criteria, based on
the eGFR at the time of transplantation, for determining
when a combined transplant strategy would be advanta-
geous. Central to a discussion of combined organ transplan-
tation is the question of whether native renal function will
improve following heart transplantation alone. Although
our study cannot provide a definitive answer to this impor-
tant question, we do provide data suggesting that early renal
insufficiency requiring dialysis is relatively frequent among
HTx recipients, and that reduced eGFR, especially below a
threshold of 37 mL/minute, increases this risk. We also
found that despite only a modest increase in the number
of isolated HTx procedures performed yearly, combined
HKTx rates are rising more rapidly. It is likely, therefore,458 The Journal of Thoracic and Cardiovascular Surgthat initiatives to develop evidence-based guidelines for
multiorgan allocation are timely, and might be particularly
beneficial.
Our recently published article10 demonstrated that LVAD
use might optimize outcomes among HTx recipients
compared with other types of mechanical circulatory
support. Our study described here demonstrated a benefit,
as expected, among those recipients who did not require
either inotropic nor mechanical circulatory support as
well as a disadvantage to those patients requiring use of
intra-aortic balloon pump immediately before transplanta-
tion. However, there was no benefit seen among recipients
managed with LVAD versus other types of assist devices.
As elucidated in our prior manuscript, the UNOS
dataset may not provide enough granularity at present to
distinguish among types of LVAD device and UNOS also
does not allow determination of the timing of LVADery c January 2014
TABLE 1. Patient characteristics segregated by recipient type
Variable
Combined
heart-kidney
transplant
(n ¼ 593)
Isolated heart
transplant
(n ¼ 25,590) P
Age, y 51.1  13.4 45.2  20 <.001
Weight, kg 79.1  19.8 79.9  26.9 .41
Creatinine at Tx, mg/dL 3.43  2.80 1.21  0.79 <.001
Women 133 (22) 7047 (28) .006
Status 1A 109 (18) 6771 (26) <.001
Diabetes 214 (36) 5074 (20) <.001
African American 148 (25) 4423 (17) <.001
Days on waitlist 95 (1-2824) 72 (0-5815) .14
Ischemic time, h 3.2  1.1 3.3  1.1 .04
Underlying diagnosis
Dilated CM 377 (63) 18,635 (72) <.001
Ischemic CM 25 (4) 1033 (4) .82
CHD 13 (2) 2071 (8) <.001
Other 178 (29) 3851 (16) <.001
LVAD support at Tx 90 (15) 5219 (20) .003
Inotropic support at Tx 224 (38) 9298 (36) .75
IABP at Tx 26 (4) 901 (4) .58
BiVAD support at Tx 11 (2) 623 (2) .31
RVAD support 2 (.3%) 54 (.2%) .51
Values are presented as mean  standard deviation or medians (range); frequencies
are presented as n (%). Tx, Transplant; CM, cardiomyopathy; CHD, congenital
heart disease; LVAD, left ventricular assist device; IABP, intra-aortic balloon pump;
BiVAD, biventricular assist device; RVAD, right ventricular assist device.
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Ximplementation. Further studies using a dedicated dataset,
such as the Interagency Registry for Mechanically Assisted
Circulatory Support, would be insightful.
Narula and colleagues11 published the only other national
study of combined HKTx in 1997, using the UNOS.11 That
study used data from 1987-1995, circumscribing the period
that included UNOS registry inception. Eighty-four HKTx
recipients were compared with 14,340 isolated HTx
recipients. In agreement with our study, overall survival
was equivalent among both groups.FIGURE 2. Kaplan-Meier plot depicting post-transplant survival
among isolated heart transplant recipients (red line) compared with
post-transplant survival among combined heart-kidney transplant
recipients. Note that survival is equivalent among both groups.
The Journal of Thoracic and CaAs has been subsequently shown in other studies,12-14
combined transplantation reduced the prevalence of cardiac
allograft rejection. Although the putative mechanism of
reduced allograft rejection (both kidney and heart) remains
unclear, it is speculated that the organ combination induces
immunogenic tolerance.15 The study by Narula et al11 did not
report outcomes other than survival or allograft rejection, and
did not stratify patients based on pretransplant renal function.
Multiple single-institution studies of combined HKTx
have been reported.2-4,14,16,17 Raichlin and colleagues4
compared the results of 12 patients undergoing combined
organ transplantation with those of 183 patients undergoing
isolated HTx at the Mayo Clinic over a 10-year period
(1996-2007). Post-transplant survival was equivalent in
both groups, as in our study described here. Importantly,
although their numbers were small, they showed that kidney
allograft function at 1-year, as measured by GFR, remained
superior to native renal function among isolated HTx
recipients. Although the study by Raichlin and colleagues4
did not stratify patients by pre-transplant GFR, in a
subgroup of 19 isolated HTx recipients with GFR
<40 mL/minute, 7 (44%) developed end-stage renal failure
and 4 (25%) underwent kidney transplantation within 3
years. The contention that preoperative renal function
predicts the development of chronic renal insufficiency
following HTx is supported by data from both Vossler and
colleagues18 and Al Aly and colleagues.19 The study by
Vossler and colleagues18 established a mean creatinine
threshold of 1.6 mg/dL as a risk factor for chronic renal
insufficiency, whereas Al Aly and colleagues18 showed a
predictable decrement in renal function of 10 mL/minute/
1.73 m2 at 10 and 15 years as well as an increased mortality
in survivors of HTx procedure. Multiple factors contribute
to decreased renal function among HTx recipients,
including nephrotoxic immunosuppressive medications,
compromised cardiac allograft function, infection, and
exacerbation of underlying comorbidities. In our study,
there was an important prevalence (9%) of early
post-transplant dialysis among isolated HTx recipients,
and the risk of early dialysis was higher among recipients
with impaired renal function.
Czer and colleagues2 reviewed their single institution
outcomes for 30 patients undergoing combined HKTx
compared with 440 patients undergoing isolated HTx.
They also showed similar survival among both recipient
groups. Although they reported that renal function
remained equivalent among the combined recipients and
the isolated HTx recipients, there was still an 8.5%
incidence of renal failure among those receiving only
cardiac allografts.
A strength of our study is the stratification of transplant
candidates based on a reproducible and objective measure
of renal function, and the use of this marker, the eGFR, to
develop criteria in which combined transplantation isrdiovascular Surgery c Volume 147, Number 1 459
FIGURE 3. Kaplan-Meier plot depicting post-transplant survival among isolated heart-transplant recipients stratified by glomerular filtration rate (GFR)
quintiles. Note that recipients in the lowest GFR quintile (GFR<37mL/minute [red line]) had significantly lower survival compared with the other 4 groups.
Cardiothoracic Transplantation Karamlou et al
T
Xbeneficial. Stratification was possible because of the large
number of patients included in the UNOS registry.
Although others have proposed criteria, the predictions
are limited by small numbers of patients. Savdie and
colleagues20 suggested a threshold of GFR<30 mL/minute
based on 7 patients, whereas Smith and colleageus21
suggested that creatinine <2 mg/dL be used for
cardiac retransplant candidates with cyclosporine-inducedFIGURE 4. Kaplan-Meier plot depicting the post-transplant survival among
(GFR) quintile (GFR<37 mL/minute [black line]) compared with post-tran
line). Although overall survival was equivalent among both isolated heart transp
advantage when a combined transplant strategy is used compared with isolated
460 The Journal of Thoracic and Cardiovascular Surgnephrotoxicity based on 66 patients. Clearly, additional
studies are needed to refine our proposed criteria and
validate them in a prospective cohort of patients.
Limitations
Our study is a retrospective review with limited
information regarding preclinical status and timing of
interventions. Unfortunately, in 11,261 patients theisolated heart transplant recipients in the lowest glomerular filtration rate
splant survival among combined heart-kidney transplant recipients (red
lant and combined organ transplant recipients, there is a significant survival
heart transplant in the subgroup of patients with GFR<37 mL/minute.
ery c January 2014
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Xpresence or absence of renal replacement therapy was not
documented and therefore it was not possible to include
these patients in the analysis. Specific pretransplant risk
factors that could be informative regarding outcome,
including peripheral vascular disease and functional
status, were also missing in large numbers of patients
(n ¼ 11,267).
Post-transplant immunosuppression regimens are differ-
ent among recipient groups, with the combined organ
recipients likely receiving more aggressive therapy. If
this therapy favorably biased survival toward the
combined organ recipients is unknown, although equivalent
survival has been reported by multiple other groups, some
of whom adjusted for different postoperative immunosup-
pression. Although immunosuppression medications are
available as variables in the general UNOS registry, these
data were not included in the specialized dataset used for
our analysis.
Our study was focused on survival and early renal failure.
We did not investigate graft rejection and cannot provide
any information about whether or not allograft rejection
was accelerated in either group.
CONCLUSIONS
HKTx is increasing as a percentage of total HTx.
Pretransplant eGFR is an important determinant of
improved HTx recipient survival, and can also predict the
occurrence of postoperative renal failure. Combined organ
transplantation recovers post-transplant survival in patients
with eGFR<37 mL/minute and can be recommended for
potential HTx candidates in this subgroup.
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TABLE E1. Variables considered in multivariable models.
Age, y
Transplant weight, kg
Creatinine at time of transplant
Estimated glomerular filtration rate (log-transformed)
Estimated glomerular filtration rate quintile
Waitlist time, d
Highest panel reactive antibody level
Most recent panel reactive antibody level
Ischemic time, h
Status at listing
Female sex
Race (ie, white, African American, Hispanic, Asian, other)
Blood group
Diabetes
Diabetes duration>5 y
Transplant year
Inotropic or mechanical circulatory support types
Underlying diagnosis (eg, congenital heart disease, dilated
cardiomyopathy, restrictive cardiomyopathy)
TABLE E2. Multivariable factors among isolated heart transplant
recipients that are associated with post-transplant mortality
Variable
Hazard
ratio
95% confidence
interval P
Most recent panel reactive
antibody (per%)
1.004 1.002-1.006 <.001
Woman 1.084 1.025-1.146 .004
No support at Tx 0.831 0.775-0.892 <.001
IABP at Tx 1.189 1.070-1.321 .001
African American race 1.537 1.446-1.634 <.001
Dx of CHD 1.295 1.170-1.433 <.001
Dx of dilated CM 0.878 0.824-0.934 <.001
Dx of HCM 0.757 0.613-0.8934 <.001
Ischemic CM 1.243 1.177-1.313 <.001
Diabetes 1.167 1.100-1.239 <.001
Longer ischemic time, h 1.080 1.056-1.105 <.001
Blood type O 1.093 1.041-1.147 <.001
Most recent era 0.878 0.820-0.941 <.001
Combined HKTx 0.650 0.545-0.776 <.001
eGFR<35 mL/min (lowest quintile) 1.233 1.131-1.345 <.001
eGFR<50 mL/min (second quintile) 1.134 1.052-1.222 .001
eGFR* 0.812 0.760-0.869 <.001
Tx, Transplant; IABP, intra-aortic balloon pump; Dx, diagnosis; CHD, congenital
heart disease; CM, cardiomyopathy; HCM, hypertrophic cardiomyopathy; HKTx,
combined heart kidney transplant; eGFR, estimated glomerular filtration rate. *log
transformed.
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